Acute heart failure and cardiogenic shock

Abstract The treatment of patients with advanced acute heart failure is still challenging. Intra-aortic balloon pump (IABP) has widely been used in the management of patients with cardiogenic shock. However, according to international guidelines, its routinary use in patients with cardiogenic shock is not recommended. This recommendation is derived from the results of the IABP-SHOCK II trial, which demonstrated that IABP does not reduce all-cause mortality in patients with acute myocardial infarction and cardiogenic shock. The present position paper, released by the Italian Association of Hospital Cardiologists, reviews the available data derived from clinical studies. It also provides practical recommendations for the optimal use of IABP in the treatment of cardiogenic shock and advanced acute heart failure.

Download Full-text

GROWTH DIFFERENTIATION FACTOR-15 IS ASSOCIATED WITH MORTALITY IN PATIENTS WITH SEVERE ACUTE HEART FAILURE OR CARDIOGENIC SHOCK

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(17)34138-4 ◽

2017 ◽

Vol 69 (11) ◽

pp. 749

Author(s):

Walter S. Speidl ◽

Konstantin Krychtiuk ◽

Max Lenz ◽

Stefan Kastl ◽

Johann Wojta ◽

...

Keyword(s):

Heart Failure ◽

Cardiogenic Shock ◽

Acute Heart Failure ◽

Growth Differentiation Factor 15 ◽

Differentiation Factor

Download Full-text

Mechanical circulatory support devices in cardiogenic shock and acute heart failure

Current Opinion in Critical Care ◽

10.1097/mcc.0000000000000629 ◽

2019 ◽

Vol 25 (4) ◽

pp. 391-396 ◽

Cited By ~ 3

Author(s):

Benedikt Schrage ◽

Dirk Westermann

Keyword(s):

Heart Failure ◽

Cardiogenic Shock ◽

Acute Heart Failure ◽

Mechanical Circulatory Support ◽

Circulatory Support ◽

Mechanical Circulatory Support Devices ◽

Support Devices

Download Full-text

Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock

ESC Heart Failure ◽

10.1002/ehf2.12266 ◽

2018 ◽

Vol 5 (3) ◽

pp. 292-301 ◽

Cited By ~ 6

Author(s):

Hilde L. Orrem ◽

Per H. Nilsson ◽

Søren E. Pischke ◽

Guro Grindheim ◽

Peter Garred ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Cardiogenic Shock ◽

Acute Heart Failure ◽

Complement Activation

Download Full-text

Acute heart failure: early pharmacological therapy

10.1093/med/9780199687039.003.0052_update_001 ◽

2018 ◽

Author(s):

Jonathan R Dalzell ◽

Colette E Jackson ◽

Roy Gardner ◽

John JV McMurray

Keyword(s):

Heart Failure ◽

Cardiogenic Shock ◽

Acute Heart Failure ◽

Mechanical Circulatory Support ◽

De Novo ◽

Treatment Approach ◽

Pharmacological Therapy ◽

Current Therapy ◽

Circulatory Support ◽

Clinical Presentations

Acute heart failure syndromes consist of a spectrum of clinical presentations due to an impairment of some aspect of the cardiac function. They represent a final common pathway for a vast array of pathologies and may be either a de novo presentation or, more commonly, a decompensation of pre-existing chronic heart failure. Despite being one of the most common medical presentations, there are no definitively proven prognosis-modifying treatments. The mainstay of current therapy is oxygen and intravenous diuretics. However, within this spectrum of presentations, there is a crucial dichotomy which governs the ultimate treatment approach, i.e. the presence, or absence, of cardiogenic shock. Patients without cardiogenic shock may receive vasodilators, whilst shocked patients should be considered for treatment with inotropic therapy or mechanical circulatory support, when appropriate and where available.

Download Full-text